



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tr-PEG5-OH

| | |
|--------------------|---|
| Cat. No.: | HY-120845 |
| CAS No.: | 141282-24-8 |
| Molecular Formula: | C ₂₉ H ₃₆ O ₆ |
| Molecular Weight: | 480.59 |
| Target: | ADC Linker; PROTAC Linkers |
| Pathway: | Antibody-drug Conjugate/ADC Related; PROTAC |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | | |
|---------------------------|---|------|
| Description | Tr-PEG5-OH is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Tr-PEG5-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. | |
| IC ₅₀ & Target | Non-cleavable | PEGs |
| In Vitro | ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker ^[1] . PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |

REFERENCES

- [1]. Branderhorst HM, et al. Strong inhibition of cholera toxin binding by galactose dendrimers. Chem Commun (Camb). 2007 Dec 21;(47):5043-5.
- [2]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA